{"id":779650,"date":"2023-08-23T11:08:58","date_gmt":"2023-08-23T15:08:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/"},"modified":"2023-08-23T11:08:58","modified_gmt":"2023-08-23T15:08:58","slug":"altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/","title":{"rendered":"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13"},"content":{"rendered":"
\n

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th<\/sup>\u00a0Annual Global Investment Conference, being held virtually and in person\u00a0on\u00a0September 11-13, 2023, at\u00a0Lotte New York Palace Hotel in New York City.\u00a0\u00a0<\/p>\n

\n Event<\/b>: H.C. Wainwright Presentation On-Demand
Date<\/b>: September 11, 2023
Time<\/b>: 7:00am ET
Webcast<\/b>:\u00a0Link<\/u><\/a>
Registration<\/b>:\u00a0Link<\/u><\/a><\/p>\n

Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.\u00a0To schedule a 1×1 investor meeting with Mr. Thomas Meyer, please send an email to\u00a0meetings@hcwco.com<\/u><\/a>.\u00a0<\/p>\n

\n About Altamira Therapeutics<\/b>
\n
Altamira (Nasdaq: CYTO) is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore\u2122 \/ SemaPhore\u2122 delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The versatile delivery platform is also suited for mRNA and other types of RNA therapeutics and is planned to be leveraged via out-licensing to pharma or biotech companies. In addition, Altamira is in the process of divesting and\/or out-licensing its legacy assets in allergology and viral infection (Bentrio\u00ae OTC nasal spray; commercial) and inner ear therapeutics (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen\u00ae and Sonsuvi\u00ae for tinnitus and hearing loss; Phase 3). Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit:\u00a0https:\/\/altamiratherapeutics.com\/<\/u><\/a><\/p>\n

\n Forward-Looking Statements<\/b>
\n
This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of the continued commercialization of Bentrio and success of strategic transactions, including licensing or partnering, with respect to Bentrio or any other legacy assets, Altamira\u2019s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira\u2019s\u00a0\u00a0product candidates, the clinical utility of Altamira\u2019s\u00a0\u00a0product candidates, the timing or likelihood of regulatory filings and approvals, Altamira\u2019s\u00a0\u00a0intellectual property position and Altamira\u2019s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira\u2019s\u00a0\u00a0capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Altamira\u2019s\u00a0\u00a0Annual Report on Form 20-F for the year ended December 31, 2022, and in Altamira\u2019s other filings with the Securities Exchange Commission (\u201cSEC\u201d), which are available free of charge on the\u00a0\u00a0SEC\u2019s website at:\u00a0www.sec.gov<\/u><\/a>. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.<\/p>\n

\n \n <\/p>\n


\n
\n \n <\/div>\n

\n
Investor Contacts\r\nHear@altamiratherapeutics.com\r\n800-460-0183<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th\u00a0Annual Global Investment Conference, being held virtually and in person\u00a0on\u00a0September 11-13, 2023, at\u00a0Lotte New York Palace Hotel in New York City.\u00a0\u00a0 Event: H.C. Wainwright Presentation On-DemandDate: September 11, 2023Time: 7:00am ETWebcast:\u00a0LinkRegistration:\u00a0Link Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.\u00a0To schedule a 1×1 investor meeting with … <\/p>\n
Continue reading “Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global  Investment Conference September 11-13”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-779650","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAltamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th\u00a0Annual Global Investment Conference, being held virtually and in person\u00a0on\u00a0September 11-13, 2023, at\u00a0Lotte New York Palace Hotel in New York City.\u00a0\u00a0 Event: H.C. Wainwright Presentation On-DemandDate: September 11, 2023Time: 7:00am ETWebcast:\u00a0LinkRegistration:\u00a0Link Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.\u00a0To schedule a 1×1 investor meeting with … Continue reading "Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-23T15:08:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13\",\"datePublished\":\"2023-08-23T15:08:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/\"},\"wordCount\":711,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/\",\"name\":\"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=\",\"datePublished\":\"2023-08-23T15:08:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/","og_locale":"en_US","og_type":"article","og_title":"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Market Newsdesk","og_description":"HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th\u00a0Annual Global Investment Conference, being held virtually and in person\u00a0on\u00a0September 11-13, 2023, at\u00a0Lotte New York Palace Hotel in New York City.\u00a0\u00a0 Event: H.C. Wainwright Presentation On-DemandDate: September 11, 2023Time: 7:00am ETWebcast:\u00a0LinkRegistration:\u00a0Link Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.\u00a0To schedule a 1×1 investor meeting with … Continue reading \"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-23T15:08:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13","datePublished":"2023-08-23T15:08:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/"},"wordCount":711,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/","name":"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=","datePublished":"2023-08-23T15:08:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg5OTA5MiM1NzY4MzA0IzIyMTAxMTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altamira-therapeutics-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-september-11-13\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/779650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=779650"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/779650\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=779650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=779650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=779650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}